Canada markets open in 4 hours 44 minutes

AIM ImmunoTech Inc. (AIM)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.4430+0.0040 (+0.91%)
At close: 04:00PM EDT
0.4600 +0.02 (+3.84%)
After hours: 07:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.4390
Open0.4500
Bid0.4300 x 3000
Ask0.5100 x 900
Day's Range0.4300 - 0.4560
52 Week Range0.3200 - 0.7500
Volume152,525
Avg. Volume176,186
Market Cap21.637M
Beta (5Y Monthly)-0.12
PE Ratio (TTM)N/A
EPS (TTM)-0.4300
Earnings DateApr 02, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

    OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the

  • GlobeNewswire

    AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

    Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Erasmus Medical Center Erasmus Medical Center OCALA, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the publication of new data analysis from a long-term Early Access Program (“EAP”) studying the company’s drug Ampligen® (rintatolimod) for the treatment of advanced pancreatic ductal adenocarcinoma (“PDAC”). The manuscript

  • GlobeNewswire

    AIM ImmunoTech Announces Release of the Next CEO Corner Segment

    OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, provided a corporate overview, a business outlook and discussed the AIM opportunity as part of the Virtual Investor Lunch Break series. The CEO Corner segment is now available here. About AIM ImmunoTech Inc. AI